Endocrine Therapy Plus Ribociclib Provides PFS Benefit Among Patients With Breast Cancer Who Progress on CDK4/6 Inhibitors
Kevin Kalinsky, MD, Winship Cancer Institute, Emory University, Atlanta, GA, discusses findings from a phase 2 study exploring the efficacy of fulvestrant or exemestane with or without ribociclib in patients with HR-positive, HER2-negative metastatic breast cancer after progression on CDK 4/6 inhibitor therapy and any endocrine therapy.
The findings of this study were presented at the 2022 ASCO Annual Meeting.
Transcript:
In progress
Source:
Kalinsky K, Accordino MK, Chiuzan C, et al. A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. Presented at: ASCO Annual Meeting; June 3-7, 2022. Chicago, IL, and virtual. Abstract LBA1004.
